Trials / Withdrawn
WithdrawnNCT00304668
A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa
A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel (TMC120 Gel-002) vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- International Partnership for Microbicides, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Approximately 42 HIV-negative women, aged \>18 and \< 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving Dapivirine Gel-002 versus placebo. The volunteers will receive investigational product for a total of 42 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dapivirine (TMC120) vaginal gel |
Timeline
- First posted
- 2006-03-20
- Last updated
- 2015-12-10
Source: ClinicalTrials.gov record NCT00304668. Inclusion in this directory is not an endorsement.